CBD Brands, a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (CBD) via a multitude of convenient products, announced today it is appointing Dr. Hector Alila to its Board of Directors. Dr. Alila, brings 30 years of demonstrated leadership in the biopharmaceutical industry and has served as the Founding President and Chief Executive Officer of Esperance Pharmaceutical Inc. for the past 13 years. His experience in guiding the Houston-based Esperance through the clinical development of novel, targeted cancer therapeutics will be key in his role with CBD Brands as he helps lead the company’s innovative and nascent research into the medical and therapeutic uses of CBD in fighting various diseases.
Today CBD Brands, a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (CBD) via a multitude of convenient products, announced that it has appointed Dr. Glynn Wilson to its Board of Directors. Dr. Wilson, who previously served as the Chairman & CEO of TapImmune, Inc. prior to its merger with Marker Therapeutics, Inc., will draw from his more than 20 years of experience in the pharmaceutical industry to help expand clinical trials and research into the effectiveness of cannabidiol in the treatment of cancer as well as in combination therapy with existing cancer treatments on the market.